Construction of a programmed activation nanosystem based on intracellular hypoxia in cisplatin-resistant tumor cells for reversing cisplatin resistance
Source abstract
Abstract
Cancer poses a significant threat to human life and health. Cancers treated with cisplatin invariably develop drug resistance. This challenge can be overcome by identifying and exploiting the vulnerabilities acquired by drug-resistant cancer cells, paving the way for finding effective novel treatment options for cisplatin-resistant cancers. Our previous study revealed that cisplatin resistance in cancer cells comes at the cost of increased intracellular hypoxia. In this study, we used 2-nitroimidazole modified hyaluronic acid (HA-NI) as the carrier. The cisplatin-resistant tumor cell specific intracellular hypoxia programmed activation nanomedicine (T/C@HN NPs) was constructed by the hypoxic toxic drug tirapazamine (TPZ) and encapsulating chlorin e6 (Ce6) into HA-NI using polymer assembly technology. The amphiphilic carrier could release free Ce6 molecules under the stimulation of intracellular hypoxic environment, and exhibit specific "activated state" photodynamic properties in cisplatin-resistant tumor cells. Upon irradiation, Ce6-mediated photodynamic therapy further intensifies hypoxia, amplifying its cytotoxicity. This project systematically evaluated the effects of T/C@HN NPs on the identification and recognition of cisplatin-resistant tumors using drug-resistant patient-derived xenograft (PDX) models. This study provides a promising avenue for the development of novel treatment of cisplatin-resistant tumors.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Photodynamic Therapy Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (58)
Show source-provided references
1. Platinum-based combination nanomedicines for cancer therapy10.1016/j.cbpa.2023.102290 ↗
2. H-dot mediated nanotherapeutics mitigate systemic toxicity of platinum-based anticancer drugs10.3390/ijms242015466 ↗
3. Platinum prodrug nanoparticles with COX-2 inhibition amplify pyroptosis for enhanced chemotherapy and immune activation of pancreatic cancer10.1002/adma.202310456 ↗
4. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis10.1016/j.cmi.2023.08.029 ↗
5. Rewiring chaperone-mediated autophagy in cancer by a prion-like chemical inducer of proximity to counteract adaptive immune resistance10.1016/j.drup.2023.101037 ↗
6. Magnetic nanoparticles for ferroptosis cancer therapy with diagnostic imaging
7. Carvedilol for prevention of chemotherapy-related cardiotoxicity10.1016/j.jacc.2018.02.049 ↗
8. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery10.1097/SLA.0000000000005799 ↗
9. Exosomal circular RNAs: a chief culprit in cancer chemotherapy resistance10.1016/j.drup.2023.100937 ↗
10. Recent progress in nanomedicine for enhanced cancer chemotherapy10.7150/thno.57828 ↗
11. KYNU expression promotes cisplatin resistance in esophageal cancer10.7150/jca.93229 ↗
12. Optimal administration strategy in chemotherapy regimens using multi-drug cell-cycle specific tumor growth models
13. A multi-drug pharmacokinectic optimal control approach in cancer chemotherapy10.1007/s10957-022-02085-0 ↗
14. Reversing multi-drug resistance by polymeric metformin to enhance antitumor efficacy of chemotherapy10.1016/j.ijpharm.2022.121931 ↗
15. The resurgence of platinum-based cancer chemotherapy10.1038/nrc2167 ↗
16. Molecular mechanisms of cisplatin resistance10.1038/onc.2011.384 ↗
17. Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology10.1177/1559325820936161 ↗
18. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review10.2217/imt-2021-0074 ↗
19. Nuclear-targeting lipid Pt IV prodrug amphiphile cooperates with siRNA for enhanced cancer immunochemotherapy by amplifying Pt-DNA adducts and reducing phosphatidylserine exposure10.1021/jacs.3c12706 ↗
20. Tumor acidic microenvironment-induced drug release of RGD peptide nanoparticles for cellular uptake and cancer therapy10.1016/j.colsurfb.2021.111673 ↗
21. Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment10.7150/thno.37198 ↗
22. Bioorthogonal guided activation of cGAS-STING by AIE photosensitizer nanoparticles for targeted tumor therapy and imaging10.1002/adma.202305668 ↗
23. A specific targeted enhanced nanotherapy strategy for inducing ferroptosis by regulating the iron pool levels in tumor cells10.1021/acsami.4c13534 ↗
24. Prodrug-based nano-delivery strategy to improve the antitumor ability of carboplatin in vivo and in vitro10.1080/10717544.2021.1938754 ↗
25. A NAG-guided nano-delivery system for redox- and pH-triggered intracellularly sequential drug release in cancer cells10.2147/IJN.S226249 ↗
26. Alteronol enhances the anti-tumor activity and reduces the toxicity of high-dose adriamycin in breast cancer10.3389/fphar.2019.00285 ↗
27. An acquired vulnerability of drug-resistant melanoma with therapeutic potential10.1016/j.cell.2018.04.012 ↗
28. Morusin, a novel inhibitor of ACLY, induces mitochondrial apoptosis in hepatocellular carcinoma cells through ROS-mediated mitophagy10.1016/j.biopha.2024.117510 ↗
29. A novel mechanism of 6-methoxydihydroavicine in suppressing ovarian carcinoma by disrupting mitochondrial homeostasis and triggering ROS/MAPK mediated apoptosis
30. Near-infrared-II light induced mild hyperthermia activate cisplatin-artemisinin nanoparticle for enhanced chemo/chemodynamic therapy and immunotherapy10.1002/smtd.202200379 ↗
31. Understanding the warburg effect: the metabolic requirements of cell proliferation10.1126/science.1160809 ↗
32. Cancer cell metabolism: warburg and beyond10.1016/j.cell.2008.08.021 ↗
33. Targeting cancer metabolism: a therapeutic window opens10.1038/nrd3504 ↗
34. SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism10.1158/1541-7786.MCR-07-2130 ↗
35. A natural compound-empowered podophyllotoxin prodrug nanoassembly magnifies efficacy-toxicity benefits in cancer chemotherapy
36. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism10.1016/j.canlet.2016.01.009 ↗
37. Self-enhanced targeted nanomedicines based on iron starvation acclimation for tumor-specific therapy10.1016/j.cej.2024.153371 ↗
38. Tumour hypoxia causes DNA hyper-methylation by reducing TET activity10.1038/nature19081 ↗
39. The anti-tumor efficacy of 20(S)-protopanaxadiol, an active metabolite of ginseng, according to fasting on hepatocellular carcinoma10.1016/j.jgr.2021.06.002 ↗
40. Breaking the intracellular redox balance with diselenium nanoparticles for maximizing chemotherapy efficacy on patient-derived xenograft models10.1021/acsnano.0c06190 ↗
41. Exploiting the acquired vulnerability of cisplatin-resistant tumors with a hypoxia-amplifying DNA repair-inhibiting (HYDRI) nanomedicine10.1126/sciadv.abc5267 ↗
42. Versatile nanomaterials that interfere with ferroptosis in the tumor microenvironment10.2147/IJN.S508767 ↗
43. A hypoxia-responsive albumin-based nanosystem for deep tumor penetration and excellent therapeutic efficacy10.1002/adma.201901513 ↗
44. MnOOH-catalyzed autoxidation of glutathione for reactive oxygen species production and nanocatalytic tumor innate immunotherapy10.1021/jacs.2c12942 ↗
45. Efficient piezocatalytic H2O2 production of atomic-level thickness Bi4Ti3O12 nanosheets with surface oxygen vacancy
46. Boosting ferroptosis via abplatin (iv) for treatment of platinum-resistant recurrent ovarian cancer10.1016/j.nantod.2022.101459 ↗
47. Modulating hypoxia via nanomaterials chemistry for efficient treatment of solid tumors10.1021/acs.accounts.8b00214 ↗
48. Magnesium silicide nanoparticles as a deoxygenation agent for cancer starvation therapy10.1038/nnano.2016.280 ↗
49. Openwork@Dendritic mesoporous silica nanoparticles for lactate depletion and tumor microenvironment regulation10.1002/anie.202001469 ↗
50. The effect of lengths of branched-chain fatty alcohols on the efficacy and safety of docetaxel-prodrug nanoassemblies10.1016/j.apsb.2023.09.017 ↗
51. Hypoxia-triggered tumor specific glutamine inhibition for reversing cisplatin resistance of chemotherapy10.1016/j.cej.2023.147692 ↗
52. Light-triggered retention and cascaded therapy of albumin-based theranostic nanomedicines to alleviate tumor adaptive treatment tolerance10.1002/adfm.201707291 ↗
53. Allyl-, butyl- and phenylethyl-isothiocyanate modulate Akt-mTOR and cyclin-CDK signaling in gemcitabine- and cisplatin-resistant bladder cancer cell lines10.3390/ijms231910996 ↗
54. Determination of the critical micelle concentration by absorbance and fluorescence techniques using fluorescein probe10.1016/j.cplett.2019.06.038 ↗
55. Determination of the critical premicelle concentration, first critical micelle concentration and second critical micelle concentration of surfactants by resonance Rayleigh scattering method without any probe10.1016/j.saa.2011.01.018 ↗
56. Metabolic pathway analysis using stable isotopes in patients with cancer10.1038/s41568-023-00632-z ↗
57. Moderate constraint facilitates association and force-dependent dissociation of HA-CD44 complex10.3390/ijms24032243 ↗
58. Overexpressed CD44 is associated with B-cell activation via the HA-CD44-AIM2 pathway in lupus B cells10.1016/j.clim.2023.109710 ↗